<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01621750</url>
  </required_header>
  <id_info>
    <org_study_id>300-08</org_study_id>
    <nct_id>NCT01621750</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Clopidogrel Bisulfate 300 mg Tablets of Dr. Reddy's Laboratories Ltd., India and Plavix® (Clopidogrel Bisulfate) 300 mg Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the bioavailability and characterize the pharmacokinetic profile of the Sponsor's
      formulation (Clopidogrel Bisulfate 300 mg Tablets) with respect to the reference formulation
      (Plavix® 300 mg tablets) in healthy, adult, human, male subjects under fasting conditions and
      to assess the bioequivalence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two treatment, two sequence, two period, single-dose,
      crossover oral bioequivalence study of Clopidogrel Bisulfate 300 mg Tablets of Dr. Reddy's
      Laboratories Ltd., India and Plavix® (Clopidogrel Bisulfate) 300 mg Tablets of Bristol-Myers
      Squibb/Sanofi pharmaceuticals partnership Bridgewater, NJ 0880750086441, USA, in healthy,
      adult, human male subjects under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve(AUC)</measure>
    <time_frame>at pre-dose 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 20.00, 24.00, 36.00 and 48.00 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plavix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel Tablet 300 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel Tablets 300 mg</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Plavix</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult human male volunteers between 18 and 55 years of age (both inclusive)
             living in and around Ahmedabad city of western part of India.

          -  Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as
             weight in kg/height in m2.

          -  Not having any significant diseases or clinically significant abnormal findings during
             screening, medical history, clinical examination, laboratory evaluations, 12-lead ECG
             and X-ray chest (postero-anterior view) recordings.

          -  Able to understand and comply with the study procedures, in the opinion of the
             Principal investigator.

          -  Able to give voluntary written consent for participation in the trial.

        Exclusion Criteria:

          -  Known hypersensitivity or idiosyncratic reaction to Clopidogrel or any related drug.

          -  History or presence of any disease or condition which might compromise the
             haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular,
             immunological, dermatological, gastrointestinal or any other body system.

          -  Ingestion of any medication at any time in 14 days prior to the dosing of Period-I. In
             any such case subject selection was at the discretion of the Principal Investigator.

          -  Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or
             NSAID induced urticaria.

          -  A recent history of alcoholism (less than 2 years) or daily consumption of moderate
             (180 mL / day) alcohol use or consumption of alcohol within 48 hours prior to
             receiving the study medicine.

          -  The presence of clinically significant abnormal laboratory values including APTT and
             PT during screening.

          -  Consumption of grapefruit and/or grapefruit products within 48hrs prior to dosing.

          -  Use of any recreational drugs or history of drug addiction or testing positive in
             pre-study drug scans.

          -  History of psychiatric disorders.

          -  A history of difficulty in donating blood.

          -  Donation of blood (1 unit or 350 mL) within 90 days prior to receiving the first dose
             of IP.

        Note: In case the blood loss was less than or equal to 200 mL; subject was enrolled 60 days
        after blood donation.

          -  Smokers, who smoked more than 10 cigarettes / day or inability to abstain from smoking
             during the study.

          -  A positive hepatitis screen including hepatitis B surface antigen, HCV antibodies.

          -  A positive test result for HIV antibody and/or syphilis.

          -  The receipt of an investigational product or participation in a drug research study
             within a period of 90 days prior to the first dose of study medication. Elimination
             half-life of the study drug was taken into consideration for inclusion of the subject
             in the study.

        Note: If subject had participated in a study in which blood loss was less than or equal to
        200 mL, subject was dosed 60 days after the last sample of previous study.

          -  An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to
             receiving the study medication and throughout the subjects' participation in the
             study. In any such case subject selection was at the discretion of the Principal
             Investigator.

          -  Any history of peptic ulcer disease, which include gastric &amp; duodenal ulcer or any
             other bleeding disorders.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Yogesh Gulati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Ltd.,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2012</study_first_posted>
  <last_update_submitted>June 14, 2012</last_update_submitted>
  <last_update_submitted_qc>June 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

